Evidence map›Paper›PMID 29984766›Full record

ReviewInternal medicine (Tokyo, Japan)2018

Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review.

Hajime Sasano, Akimasa Sekine, Toru Hirata, Keisuke Iwamoto, Yuhei Itou, Hidetoshi Itani, Shigeto Kondou, Toshiya Tokui, Motoaki Tanigawa

Open access · diamondAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Ovarian metastases fromTranslational cancer research · 2022
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hajime SasanoDepartment of Respiratory Medicine, Japanese Red Cross Ise Hospital, Japan.
Akimasa SekineDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Toru HirataDepartment of Obstetrics and Gynecology, Japanese Red Cross Ise Hospital, Japan.
Keisuke IwamotoDepartment of Respiratory Medicine, Japanese Red Cross Ise Hospital, Japan.
Yuhei ItouDepartment of Respiratory Medicine, Japanese Red Cross Ise Hospital, Japan.
Hidetoshi ItaniDepartment of Respiratory Medicine, Japanese Red Cross Ise Hospital, Japan.
Shigeto KondouDepartment of Respiratory Medicine, Japanese Red Cross Ise Hospital, Japan.
Toshiya TokuiDepartment of Thoracic Surgery, Japanese Red Cross Ise Hospital, Japan.
Motoaki TanigawaDepartment of Respiratory Medicine, Japanese Red Cross Ise Hospital, Japan.
Ise Red Cross Hospital · JPKanagawa Cardiovascular and Respiratory Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a 37-year-old woman with lung adenocarcinoma with brain metastases and an asymptomatic ovarian tumor. Immunohistochemistry and a fluorescent in situ hybridization analysis of the biopsied lung tumor revealed anaplastic lymphoma kinase (ALK) gene rearrangement. Although the origin of the ovarian tumor remained unclear, alectinib administration was initiated, and radiological responses were observed in all lesions, which confirmed that the ovarian tumor was a metastasis from lung cancer. Although differentiating the origin of an ovarian tumor is difficult in lung cancer patients due to the rarity of ovarian metastases, alectinib therapy can replace an invasive biopsy, especially in ALK-rearranged lung cancer patients.

Indexed as

Gene RearrangementAdenocarcinoma of LungAdultAnaplastic Lymphoma KinaseBiomarkers, TumorBiopsyFemaleHumansIn Situ Hybridization, FluorescenceMagnetic Resonance ImagingOvarian NeoplasmsTomography, X-Ray ComputedAnaplastic Lymphoma KinaseBiomarkers, TumorAlectinibALK-rearranged lung adenocarcinomametastatic ovarian tumor

Identifiers

PMID29984766
PMCPMC6287983
OpenAlexW2860317377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.